Van Lanschot Kempen raises its target price for Danish pharmaceutical company Genmab to DKK 3,300 from DKK 2,900 with a Buy recommendation and continues to rank the stock among its sector favorites. This is according to an analysis seen by Bloomberg.
Kempen describes the coming quarter as decisive, with Phase 3 results for petosemtamab, Epkinly and Rina-S. The results for petosemtamab in the first-line treatment of head and neck cancer are expected to be the most significant.
The research house sees good prospects for a positive outcome and assesses that the study could provide a significant boost to the valuation.
Kempen’s new target price for Genmab is reportedly the highest among analysts covering the company.
